Merry Christmas-Kwanzaa-Hanukkah and happy holidays to all. It has been a busy week within the stem cell industry. Check it our industry coverage and let me know what you think?
Pairing Cord Blood and Tissue Storage with Genetic Testing Services
One of the most prominent trends within the global cord blood banking industry is the pairing of cord blood and tissue storage with genetic testing services. The rise of this trend is driven by the ability of cord blood storage providers to offer complimentary services to existing clients, thereby expanding and diversifying their product portfolio.
Exosome Research: Who Is Dominating in the Scientific Literature?
When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and Chinese authors take second place. When the term “exosome” is searched within the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author, with 37 articles. When the term “extracellular vesicles” is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead.
Exosome Market Witnesses Surge of Strategic Partnerships
Because the therapeutic applications of stem cell exosomes are expanding, innovation within the market is also accelerating. Recently, a great deal of venture capital funding has been flowing into the exosome market. However, market activity has not been limited to funding events. There has also been a great deal of partnering activity.
With an aging population, obesity on the rise, and sedentary lifestyles becoming increasingly common, diabetes has grown into a major health concern. According to the Center for Disease Control (CDC), 29.1 million people or 9.3% of the U.S. population has diabetes, including an estimated 8.1 million who are undiagnosed. Given the growing promise of cellular therapies, the following companies are exploring cell-based treatments for diabetes.
Gilead Sciences and Kite Expand CAR-T Domination with Acquisition of Cell Design Labs
Gilead Sciences and its cell therapy subsidiary Kite have entered into a definitive agreement to acquire Cell Design Labs, Inc., gaining new technology platforms that will expand Gilead's pipeline of CAR-T products. Gilead will acquire all of the outstanding shares of Cell Design Labs, which includes the approximately 12.2% of shares of Cell Design Labs that are currently held by Kite, for up to $567 million.
Janssen Biotech, a J&J subsidiary, has entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland to develop, manufacture and commercialize a chimeric antigen receptor (CAR) T-cell drug candidate, LCAR-B38M. LCAR-B38M is the first CAR-T therapy accepted for review by the China Food and Drug Administration (CFDA) and in the planning phase of clinical studies in the U.S. for multiple myeloma.
Explosion of Interest in Exosome Technologies and Companies Leading the Charge
Although long overlooked, exosomes are rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. Exosomes also have enormous potential for use as biomarkers in non-invasive tests, vehicles for drug delivery, and active agents in cosmeceutical products. On the venture capital front, exosomes are receiving funding support with accelerating velocity.
Evox Therapeutics to Collaborate with Boehringer Ingelheim on Exosome-Mediated Drug Delivery
Evox Therapeutics, a leading exosome therapeutics company, has entered into a research collaboration with Boehringer Ingelheim to investigate exosome-mediated delivery of RNAs with high medical relevance to targets for specific disease areas of focus to Boehringer Ingelheim. The collaboration is part of Boehringer Ingelheim’s Research Beyond Borders (RBB) initiative.
Pharma Industry Accelerating Investment into Cell Therapy Companies
An accelerating trend within the pharmaceutical industry is investment into or acquisition of cell therapy companies. At its core, this is a strategic way for pharmaceutical companies to diversity their product development pipeline. Most recently, Japanese drugmaker Otsuka Holdings acquired a 10% (1 billion yen) stake in Megakaryon, a venture that creates platelets out of iPS cells.
The Market for Stem Cell Exosomes
This 134-page global strategic report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials, as well as social analytics from Google Trends and Google Adwords. It explores the growing demand for exosome therapeutics, diagnostics, research tools, consumer care products, and manufacturing processes. It identifies the five market segments forming the industry, reveals the market player competing in each niche, presents market size determinations with 5-year projections, and identifies opportunities for commercializing exosome products.
Complete 2017-18 Global Cord Blood Banking Industry Report
Recently released, this 265-page global strategic report reveals key benchmarks to track and why you should care. Benchmarks are critical to assess, because the cord blood banking industry has matured substantially over the past few years, creating both serious threats and novel opportunities. Therefore, judging individual company performance relative to the broader cord blood marketplace has become substantially more complex. With approximately 450 companies marketing cord blood banking services worldwide, maturation of the market means that each company is fighting harder for market share.
Be Great,
Cade President/CEO of BioInformant.com "1st and Only Market Research Firm to Specialize in the Stem Cell Industry"
p.s. The 2018 Regenerative Medicine Industry Database is launching tomorrow. It features more than 600+ companies worldwide, positioning you to assess market competition or sell your products/services into this RAPIDLY growing marketplace.
|
|
|
